跳至主要内容
临床试验/ACTRN12613001222730
ACTRN12613001222730已完成3 期

A phase III study to investigate the effect of daily ingestion of four then two Kivia (Trademark) 575mg Zyactinase (Registered Trademark) or placebo capsules on stool frequency and abdominal pain severity when given to subjects with constipation dominant Irritable Bowel Syndrome

Vital Food Processors Ltd0 个研究点目标入组 180 人开始时间: 2013年11月6日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • Subjects diagnosed with IBS-C according to Rome III criteria Abdominal pain intensity in past 24 hour score of >3.0 using VAS scale during screening
  • Subject swith Fewer than 3 Complete Spontaneous Bowel Movements per week during screening

排除标准

  • Diarrhoea predominant or alternating IBS
  • Significant GI condition or serious systemic illness

研究者

发起方
Vital Food Processors Ltd

相似试验